The Structural Genomics Consortium at the University of North Carolina at Chapel Hill (SGC-UNC) is a team of scientists dedicated to discovering and sharing selective, small molecule chemical probes of the dark proteome. Their work aims to facilitate the discovery of new molecular targets for drug discovery and help speed the creation of new medicines for patients.
The UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill houses the first U.S. site of the SGC, a public-private target discovery consortium that catalyzes research in new areas of human biology and drug discovery. The main SGC-UNC research programs include:
- Develop chemical probes and NanoBRET assays for dark kinases in support of the Illuminating the Druggable Genome consortium
- Develop chemical probes for viral pathogens of pandemic potential for the READDI Antiviral Drug Discovery Center
- Develop chemical probes to validate proteins associated with Alzheimer’s disease for the TREAT-AD consortium